Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Up 5.8% in February

Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 19,060,000 shares, an increase of 5.8% from the February 13th total of 18,010,000 shares. Based on an average daily volume of 2,320,000 shares, the short-interest ratio is currently 8.2 days. Approximately 15.8% of the company’s shares are sold short.

Insider Activity

In other news, Director Lynne Chou O’keefe sold 10,044 shares of Hims & Hers Health stock in a transaction on Monday, December 19th. The stock was sold at an average price of $6.72, for a total value of $67,495.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Lynne Chou O’keefe sold 10,044 shares of Hims & Hers Health stock in a transaction on Monday, December 19th. The stock was sold at an average price of $6.72, for a total value of $67,495.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David B. Wells sold 100,000 shares of Hims & Hers Health stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $9.77, for a total value of $977,000.00. Following the completion of the transaction, the director now owns 340,357 shares in the company, valued at approximately $3,325,287.89. The disclosure for this sale can be found here. Insiders sold a total of 675,788 shares of company stock valued at $7,333,875 over the last quarter. Company insiders own 35.22% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Lazard Asset Management LLC bought a new position in shares of Hims & Hers Health during the 3rd quarter worth about $51,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Hims & Hers Health during the 3rd quarter worth about $616,000. Jupiter Asset Management Ltd. bought a new position in shares of Hims & Hers Health during the 3rd quarter worth about $1,244,000. Teacher Retirement System of Texas lifted its holdings in shares of Hims & Hers Health by 41.9% during the 3rd quarter. Teacher Retirement System of Texas now owns 17,123 shares of the company’s stock worth $96,000 after acquiring an additional 5,057 shares during the period. Finally, MQS Management LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth about $96,000. Institutional investors own 45.60% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS opened at $9.74 on Friday. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -30.44 and a beta of 0.49. The business’s 50-day moving average is $8.75 and its 200-day moving average is $6.83. Hims & Hers Health has a fifty-two week low of $2.72 and a fifty-two week high of $12.04.

Hims & Hers Health (NYSE:HIMS – Get Rating) last released its earnings results on Monday, February 27th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. Hims & Hers Health had a negative net margin of 12.47% and a negative return on equity of 20.69%. The company had revenue of $167.30 million during the quarter, compared to the consensus estimate of $161.18 million. During the same quarter in the prior year, the firm earned ($0.11) EPS. The company’s revenue was up 97.5% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health will post -0.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Credit Suisse Group lifted their price target on shares of Hims & Hers Health from $8.00 to $14.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 1st. Piper Sandler lifted their price objective on shares of Hims & Hers Health from $7.00 to $10.00 and gave the stock a “neutral” rating in a report on Tuesday, February 28th. Tigress Financial lifted their price objective on shares of Hims & Hers Health from $11.00 to $12.00 in a report on Tuesday, January 10th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $7.00 to $9.00 in a report on Wednesday, March 1st. Finally, Truist Financial lifted their price objective on shares of Hims & Hers Health from $7.00 to $12.00 and gave the stock a “hold” rating in a report on Tuesday, February 28th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $11.55.

Hims & Hers Health Company Profile

(Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.